Phathom Pharmaceuticals, Inc.
PHAT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001783183
No open-market purchases or sales by Phathom Pharmaceuticals, Inc. insiders were filed in the last 90 days; 161 institutions reported holding it in 13F filings for Q2 2026, worth $782.1M in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Phathom Pharmaceuticals, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 133
- +20 vs. Q2 2024
- Shares held
- 72.6M
- +17.5M (+31.6%) vs. Q2 2024
- Total value
- $1.31B
- +$744.3M (+130.9%) vs. Q2 2024
- New holders
- 30
- 57 more added
- Sold out
- 10
- 18 more reduced
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PHAT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 161 | $782.1M |
| Q1 2026 | 174 | $765.5M |
| Q4 2025 | 173 | $1.03B |
| Q3 2025 | 133 | $733.6M |
| Q2 2025 | 117 | $550.5M |
| Q1 2025 | 137 | $401.4M |
| Q4 2024 | 144 | $541.2M |
| Q3 2024 | 133 | $1.31B |
| Q2 2024 | 114 | $598.6M |
| Q1 2024 | 114 | $588.2M |
| Q4 2023 | 117 | $503.3M |
| Q3 2023 | 110 | $452.7M |
| Q2 2023 | 103 | $612.6M |
| Q1 2023 | 84 | $219.7M |
| Q4 2022 | 87 | $316.6M |
| Q3 2022 | 94 | $334.3M |
| Q2 2022 | 94 | $230.0M |
| Q1 2022 | 82 | $349.1M |
| Q4 2021 | 83 | $562.0M |
| Q3 2021 | 84 | $819.8M |
| Q2 2021 | 79 | $843.6M |
| Q1 2021 | 84 | $919.2M |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Phathom Pharmaceuticals, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Eagle Asset Management Inc | 455,196 | $7.67M | 0.04% | +93,733+25.9% | Added |
| Goldman Sachs Group Inc | 434,221 | $7.85M | 0.00% | +16,937+4.1% | Added |
| Morgan Stanley | 439,490 | $7.95M | 0.00% | −323,107−42.4% | Reduced |
| Point72 Asset Management, L.P. | 439,816 | $7.95M | 0.03% | +439,816 | New |
| Siren, L.L.C. | 460,753 | $8.33M | 0.42% | +460,753 | New |
| Simplify Asset Management Inc. | 521,935 | $9.44M | 0.65% | 00.0% | Unchanged |
| Kennedy Capital Management, Inc. | 728,490 | $13.2M | 0.29% | −102,416−12.3% | Reduced |
| Oracle Investment Management Inc | 749,487 | $13.6M | 10.83% | +524,487+233.1% | Added |
| Geode Capital Management, LLC | 862,918 | $15.6M | 0.00% | +56,871+7.1% | Added |
| Propel Bio Management, LLC | 869,927 | $15.7M | 9.12% | 00.0% | Unchanged |
| Saturn V Capital Management LLC | 874,590 | $15.8M | 5.65% | +281,284+47.4% | Added |
| State Street Corp | 922,788 | $16.7M | 0.00% | +137,539+17.5% | Added |
| 683 Capital Management, LLC | 1,010,000 | $18.3M | 1.86% | −390,000−27.9% | Reduced |
| Catalys Pacific, LLC | 1,122,572 | $20.3M | 16.19% | +400,610+55.5% | Added |
| GW&K Investment Management, LLC | 1,126,083 | $20.4M | 0.17% | +525,640+87.5% | Added |
| Decheng Capital LLC | 1,250,000 | $22.6M | 5.35% | +400,000+47.1% | Added |
| FMR LLC | 1,304,114 | $23.6M | 0.00% | +1,301,458+49,000.7% | Added |
| Federated Hermes, Inc. | 1,403,638 | $25.4M | 0.06% | +1,403,638 | New |
| OrbiMed Advisors LLC | 1,449,073 | $26.2M | 0.48% | +1,449,073 | New |
| Checkpoint Capital L.P. | 1,504,307 | $27.2M | 13.49% | +629,307+71.9% | Added |
| Gilder Gagnon Howe & Co LLC | 1,622,883 | $29.3M | 0.35% | +150,624+10.2% | Added |
| Portolan Capital Management, LLC | 1,699,918 | $30.7M | 2.23% | +569,829+50.4% | Added |
| Avidity Partners Management LP | 1,804,493 | $32.6M | 1.66% | +184,493+11.4% | Added |
| NEA Management Company, LLC | 1,960,169 | $35.4M | 1.93% | 00.0% | Unchanged |
| Woodline Partners LP | 2,573,412 | $46.5M | 0.39% | +1,787,422+227.4% | Added |
| Ensign Peak Advisors, Inc | 2,581,388 | $46.7M | 0.08% | +336,560+15.0% | Added |
| Vanguard Group Inc | 2,696,323 | $48.7M | 0.00% | +484,568+21.9% | Added |
| BlackRock, Inc. | 3,122,570 | $56.5M | 0.00% | +3,122,570 | New |
| Carlyle Group Inc. | 3,496,808 | $63.2M | 6.63% | 00.0% | Unchanged |
| Invesco Ltd. | 4,096,762 | $74.1M | 0.01% | +953,310+30.3% | Added |
| Jennison Associates LLC | 5,866,389 | $106.1M | 0.07% | +3,108,810+112.7% | Added |
| Medicxi Ventures Management (Jersey) Ltd | 7,464,572 | $135.0M | 25.52% | 00.0% | Unchanged |
| Frazier Life Sciences Management, L.P. | 10,109,279 | $182.8M | 7.33% | 00.0% | Unchanged |
| Takeda Pharmaceutical Co Ltd | 0 | $0 | 0.00% | −1,557,063−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −112,691−100.0% | Sold out |
| Fulton Breakefield Broenniman LLC | 0 | $0 | 0.00% | −23,579−100.0% | Sold out |
| Brevan Howard Capital Management LP | 0 | $0 | 0.00% | −18,792−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −16,300−100.0% | Sold out |
| EntryPoint Capital, LLC | 0 | $0 | 0.00% | −8,503−100.0% | Sold out |
| FNY Investment Advisers, LLC | 0 | $0 | 0.00% | −5,000−100.0% | Sold out |
| Aquatic Capital Management LLC | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| Bessemer Group Inc | 0 | $0 | 0.00% | −325−100.0% | Sold out |
| Comerica Bank | 0 | $0 | 0.00% | −129−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |